111 related articles for article (PubMed ID: 36964059)
1. The safety of plasma apheresis from donors recovering from COVID-19 infection in Japan.
Kamo-Imai A; Togano T; Sato M; Kawakami Y; Inaba K; Shimazu H; Igarashi S; Tanaka K; Terada M; Kinoshita-Iwamoto N; Saito S; Kutsuna S; Hangaishi A; Morioka S; Takahashi K; Miyata S; Ohmagari N
Transfus Apher Sci; 2023 Jun; 62(3):103687. PubMed ID: 36964059
[TBL] [Abstract][Full Text] [Related]
2. The safety of COVID-19 convalescent plasma donation: A multi-institutional donor hemovigilance study.
Cho JH; Rajbhandary S; van Buren NL; Fung MK; Al-Ghafry M; Fridey JL; Dy BA; Ziman A; Schreiber GB; Gammon RR; Reik R; Stubbs JR; van Buskirk CM; Kamel H; Townsend MJ; Zeller MP; Gottschall JL
Transfusion; 2021 Sep; 61(9):2668-2676. PubMed ID: 34227689
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 convalescent plasma donor characteristics, product disposition, and comparison with standard apheresis donors.
Lasky B; Goodhue Meyer E; Steele WR; Crowder LA; Young PP
Transfusion; 2021 May; 61(5):1471-1478. PubMed ID: 33458811
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of a pilot program for COVID-19 convalescent plasma collection in Wuhan, China.
Li L; Yang R; Wang J; Lv Q; Ren M; Zhao L; Chen H; Xu H; Xie S; Xie J; Lin H; Li W; Fang P; Gong L; Wang L; Wu Y; Liu Z
Transfusion; 2020 Aug; 60(8):1773-1777. PubMed ID: 32491199
[TBL] [Abstract][Full Text] [Related]
5. Characteristics of coronavirus disease 19 convalescent plasma donors and donations in the New York metropolitan area.
Jain S; Garg K; Tran SM; Rask IL; Tarczon M; Nandi V; Kessler DA; Strauss D; Sachais BS; Yazdanbakhsh K; Rehmani S; Luchsinger L; Shi PA
Transfusion; 2021 Aug; 61(8):2374-2383. PubMed ID: 33904609
[TBL] [Abstract][Full Text] [Related]
6. Rapid development of a de novo convalescent plasma program in response to a global pandemic: A large southeastern U.S. blood center's experience.
Reik R; Gammon RR; Carol N; Smith J; Grable M; Forbes S; Wu Y; Reed L; Rogers M; Prichard A; Paul S; Scholl G
J Clin Apher; 2021 Aug; 36(4):533-546. PubMed ID: 33648025
[TBL] [Abstract][Full Text] [Related]
7. Rapid and Successful Implementation of a COVID-19 Convalescent Plasma Programme-The South African Experience.
Glatt TN; Hilton C; Nyoni C; Swarts A; Swanevelder R; Cowley J; Mmenu C; Moyo-Gwete T; Moore PL; Kutama M; Jaza J; Phayane I; Brits T; Koekemoer J; Jentsch U; Nelson D; van den Berg K; Vermeulen M
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696480
[TBL] [Abstract][Full Text] [Related]
8. Deterrents in recruitment of COVID-19 convalescent plasma donors: Experience from a hospital-based blood centre in India.
Dhiman Y; Coshic P; Pandey HC; Khatiwada B; Singh J; Mehta V; Gupta S
Transfus Med; 2021 Jun; 31(3):149-154. PubMed ID: 33749020
[TBL] [Abstract][Full Text] [Related]
9. Demographics of first-time donors returning for donation during the pandemic: COVID-19 convalescent plasma versus standard blood product donors.
Van Buren NL; Rajbhandary S; Reynolds V; Gorlin JB; Stramer SL; Notari EP; Conti G; Katz L; Stubbs JR; van Buskirk CM; Kuttner K; Smith DL; Ngamsuntikul SG; Pandey S; Ward DC; Ziman A; Hiskey M; Townsend M; Sachais BS
Transfusion; 2023 Mar; 63(3):552-563. PubMed ID: 36550639
[TBL] [Abstract][Full Text] [Related]
10. The demographic and serological characteristics of COVID-19 convalescent plasma donors: Identification of basic criteria for optimal donor selection.
Fazeli A; Sharifi S; Mohammadi S; Bahraini M; Arabkhazaeli A; Jelveh N; Eshghi P
Transfus Apher Sci; 2022 Apr; 61(2):103302. PubMed ID: 34774440
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
[TBL] [Abstract][Full Text] [Related]
12. Challenges in Establishing a Coronavirus Disease 2019 (COVID-19) Convalescent Plasma Donation Program in a Multicultural Environment.
Algora M; Mehmood T; Madison DL; AlAmeri J; Abuzakouk M; Tagamtam M; Acena L; Totaan G; Grabski G; Oumeziane N; Rajani P; Taylor L; Guzman J; AbdelWareth LO
Arch Pathol Lab Med; 2021 Dec; 145(12):1479-1484. PubMed ID: 34407176
[TBL] [Abstract][Full Text] [Related]
13. Screening donors for COVID-19 convalescent plasma.
Wang HE; Ostrosky-Zeichner L; Katz J; Wanger A; Bai Y; Sridhar S; Patel B
Transfusion; 2021 Apr; 61(4):1047-1052. PubMed ID: 33368395
[TBL] [Abstract][Full Text] [Related]
14. A retrospective study assessing the characteristics of COVID-19 convalescent plasma donors and donations.
Del Fante C; Franchini M; Baldanti F; Percivalle E; Glingani C; Marano G; Mengoli C; Mortellaro C; Viarengo G; Perotti C; Liumbruno GM
Transfusion; 2021 Mar; 61(3):830-838. PubMed ID: 33231325
[TBL] [Abstract][Full Text] [Related]
15. Convalescent Plasma the Experience and Journey from Blockbuster to Incognito: A Single Centre Experience.
Negi G; Kaur D; Jain A; Mohan YK; Meinia SK; Kaur P; Panda PK; Kalita D; Ravikant
Recent Adv Antiinfect Drug Discov; 2023; 18(3):188-196. PubMed ID: 35733306
[TBL] [Abstract][Full Text] [Related]
16. Hospital-Based Donor Recruitment and Predonation Serologic Testing for COVID-19 Convalescent Plasma.
Balcerek J; Trejo E; Levine K; Couey P; Kornberg ZV; Rogine C; Young C; Li PJ; Shy BR; Taylor JE; Bakhtary S; Friedlander T; Lynch KL; Bern C; Esensten JH
Am J Clin Pathol; 2021 Mar; 155(4):515-521. PubMed ID: 33399201
[TBL] [Abstract][Full Text] [Related]
17. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
[TBL] [Abstract][Full Text] [Related]
18. Promoting access to COVID-19 convalescent plasma in low- and middle-income countries.
Bloch EM; Goel R; Montemayor C; Cohn C; Tobian AAR
Transfus Apher Sci; 2021 Feb; 60(1):102957. PubMed ID: 32972861
[TBL] [Abstract][Full Text] [Related]
19. How we secured a COVID-19 convalescent plasma procurement scheme in Japan.
Terada M; Kutsuna S; Togano T; Saito S; Kinoshita N; Shimanishi Y; Suzuki T; Miyazato Y; Inada M; Nakamoto T; Nomoto H; Ide S; Sato M; Maeda K; Matsunaga A; Satake M; Matsubayashi K; Tsuno H; Kojima M; Kuramistu M; Tezuka K; Ikebe E; Okuma K; Hamaguchi I; Shiratori K; Sato M; Kawakami Y; Inaba K; Igarashi S; Yamauchi R; Matsumura M; Ishimaru K; Zhang B; Kuge C; Ishihara M; Gouda M; Tanaka K; Ishizaka Y; Ohmagari N
Transfusion; 2021 Jul; 61(7):1998-2007. PubMed ID: 34096059
[TBL] [Abstract][Full Text] [Related]
20. Analysis of responses of the health care workers recovered from COVID-19 on convalescent plasma donation by apheresis: A single-center survey study.
Sahu A; Prakash S; Singh AK; Mukherjee S
J Clin Apher; 2022 Jun; 37(3):273-280. PubMed ID: 35119768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
